These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28948004)

  • 1. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.
    Gou Q; Gong X; Jin J; Shi J; Hou Y
    Oncotarget; 2017 Sep; 8(36):60704-60709. PubMed ID: 28948004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth.
    Asgharzadeh F; Memarzia A; Alikhani V; Beigoli S; Boskabady MH
    Transl Oncol; 2024 Sep; 47():102039. PubMed ID: 38917593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARα regulates tumor progression, foe or friend?
    Gao J; Yuan S; Jin J; Shi J; Hou Y
    Eur J Pharmacol; 2015 Oct; 765():560-4. PubMed ID: 26409040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Guan Y; Breyer MD
    Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
    Chinetti G; Fruchart JC; Staels B
    Inflamm Res; 2000 Oct; 49(10):497-505. PubMed ID: 11089900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease.
    Boitier E; Gautier JC; Roberts R
    Comp Hepatol; 2003 Jan; 2(1):3. PubMed ID: 12622871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA; Piqueras L; Bishop-Bailey D
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
    Strakova N; Ehrmann J; Bartos J; Malikova J; Dolezel J; Kolar Z
    Neoplasma; 2005; 52(2):126-36. PubMed ID: 15800711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
    Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
    Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
    Berger J; Wagner JA
    Diabetes Technol Ther; 2002; 4(2):163-74. PubMed ID: 12079620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Expression of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer and Their Association with Cancer Progression and Prognosis.
    Yaghoubizadeh M; Pishkar L; Basati G
    Gastrointest Tumors; 2020 Apr; 7(1-2):11-20. PubMed ID: 32399461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy.
    Roman J
    J Investig Med; 2008 Feb; 56(2):528-33. PubMed ID: 18317436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of peroxisome proliferator-activated receptors in colorectal cancer.
    Park JI; Kwak JY
    PPAR Res; 2012; 2012():876418. PubMed ID: 23024650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-dependent nucleo-cytoplasmic shuttling of peroxisome proliferator-activated receptors, PPARα and PPARγ.
    Umemoto T; Fujiki Y
    Genes Cells; 2012 Jul; 17(7):576-96. PubMed ID: 22646292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
    Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
    Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
    Smeets PJ; Planavila A; van der Vusse GJ; van Bilsen M
    Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G; Torres N; Tovar AR
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.